StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of NAVB stock opened at $0.00 on Friday. The firm has a market capitalization of $100,084.00, a PE ratio of -0.02 and a beta of 1.46. Navidea Biopharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.13.
About Navidea Biopharmaceuticals
Further Reading
- Five stocks we like better than Navidea Biopharmaceuticals
- What is a Death Cross in Stocks?
- 3 Momentum Trades for October With Ample Upside Ahead
- Learn Technical Analysis Skills to Master the Stock Market
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- ETF Screener: Uses and Step-by-Step Guide
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.